A temporal lobe cystic and solid enhancing tumor (Figure 2) in a patient younger than 55 years should prompt next-generation sequencing of the tumor for BRAF mutation, in case targeted therapy may be initiated. The gene discussed is BRAF; the disease is neoplasm.